JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics (NASDAQ:HALO) had its price target boosted by equities researchers at JPMorgan Chase & Co. from $78.00 to $79.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential downside of 39.42% from the stock’s current price.

Several other analysts have also commented on the stock. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.64.

Halozyme Therapeutics Stock Up 1.1%

Shares of Halozyme Therapeutics stock traded up $1.46 on Tuesday, hitting $130.41. The company had a trading volume of 384,942 shares, compared to its average volume of 1,947,857. The stock has a market capitalization of $14.80 billion, a price-to-earnings ratio of 38.94, a P/E/G ratio of 0.49 and a beta of 0.88. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The stock has a 50 day moving average of $114.12 and a 200-day moving average of $83.74. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics will post 8.31 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the transaction, the director owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 over the last ninety days. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HALO. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the 2nd quarter worth $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the second quarter worth about $196,540,000. Jupiter Topco LLC purchased a new stake in Halozyme Therapeutics in the second quarter worth about $105,570,000. Caisse de depot et placement du Quebec purchased a new stake in Halozyme Therapeutics in the second quarter worth about $83,940,000. Finally, Congress Asset Management Co. boosted its position in Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.